SEC Comment Letter for Oncotelic Therapeutics, (OTLC) — May 27, 2021
Oncotelic Therapeutics, Inc.
Date: May 27, 2021 · CIK: 0000908259 · Accession: 0000000000-21-006679
AI Filing Summary & Sentiment
File numbers found in text: 333-256448
Letter
United States securities and exchange commission logo May 27, 2021 Vuong Trieu, Ph.D. Chief Executive Officer Oncotelic Therapeutics, Inc. 29397 Agoura Road, Suite 107 Agoura Hills, CA 91301 Re:Oncotelic Therapeutics, Inc. Registration Statement on Form S-1 Filed May 24, 2021 File No. 333-256448 Dear Dr. Trieu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jay K. Yamamoto
Show Raw Text
United States securities and exchange commission logo
May 27, 2021
Vuong Trieu, Ph.D.
Chief Executive Officer
Oncotelic Therapeutics, Inc.
29397 Agoura Road, Suite 107
Agoura Hills, CA 91301
Re:Oncotelic Therapeutics, Inc.
Registration Statement on Form S-1
Filed May 24, 2021
File No. 333-256448
Dear Dr. Trieu:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jay K. Yamamoto